FDA, Ae­tion part­ner on re­al-world da­ta an­a­lyt­ics for Covid-19

The FDA on Tues­day said it will part­ner with New York-based health tech­nol­o­gy firm Ae­tion, Inc. to de­vel­op re­al-world da­ta an­a­lyt­ics to an­swer press­ing ques­tions re­lat­ed to coro­n­avirus dis­ease (Covid-19).

“Eval­u­a­tion of re­al-world da­ta has the po­ten­tial to pro­vide a wealth of rapid, ac­tion­able in­for­ma­tion to bet­ter un­der­stand dis­ease symp­toms, de­scribe and mea­sure im­mu­ni­ty and un­der­stand avail­able med­ical prod­uct sup­plies to help mit­i­gate po­ten­tial short­ages. These da­ta can al­so in­form on­go­ing work to eval­u­ate po­ten­tial ther­a­pies, vac­cines or di­ag­nos­tics for COVID-19,” said FDA Prin­ci­pal Deputy Com­mis­sion­er Amy Aber­nethy.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER